Toggle Health Problems and D

Daily Magnesium improved all aspects of metabolic profile – RCT July 2014

Oral magnesium supplementation improves the metabolic profile of metabolically obese, normal-weight individuals: a randomized double-blind placebo-controlled trial.

Arch Med Res. 2014 Jul;45(5):388-93. doi: 10.1016/j.arcmed.2014.05.003. Epub 2014 May 13.
Rodríguez-Moran M1, Guerrero-Romero F2 guerrero.romero at gmail.com
Author information
1 Biomedical Research Unit, Mexican Social Security Institute, Durango, Mexico.
2 Biomedical Research Unit, Mexican Social Security Institute, Durango, Mexico.

VitaminDWiki Summary

Magnesium Chloride containing 386 mg Mg
Both obese and normal weight individuals had similar benefit

Systolic blood pressure -2 mm +4 mm
Diastolic blood pressure-4 mm+8 mm
HOMA-IR index -47%. -5%
Fasting glucose -12% -2% mg/dL
Triglyceride levels -47%10%

See also VitaminDWiki

Vitamin D appears to both prevent and treat diabetes

Number of articles in both categories of Diabetes and:
'This list is automatically updated''

  • Dark Skin 24;   Intervention 56;   Meta-analysis 38;   Obesity 35;  Pregnancy 44;   T1 (child) 39;  Omega-3 11;  Vitamin D Receptor 24;  Genetics 13;  Magnesium 29    Click here to see details

Some Diabetes studies

50 ng of Vitamin D fights Diabetes

T1 Diabetes


Diabetes, Metabolic Syndrome and Magnesium - many studies
The TOP Metabolic Syndrom articles are here:

We undertook this study to determine the efficacy of oral magnesium supplementation in the improvement of the metabolic profile and blood pressure in metabolically obese, normal-weight (MONW) individuals.
A total of 47 MONW individuals with hypomagnesemia were enrolled in clinical a randomized double-blind placebo-controlled trial. Individuals in the intervention group received 30 mL of MgCl2 5% solution (equivalent to 382 mg of magnesium) and individuals in the control group 30 mL of placebo solution, once daily during 4 months. In the absence of obesity or overweight, the presence of fasting glucose levels ≥100 mg/dL, HOMA-IR index ≥3, triglyceride levels ≥150 mg/dL and/or systolic and diastolic blood pressure ≥140 and 90 mmHg defined the presence of the MONW phenotype. Hypomagnesemia was defined by serum magnesium concentration ≤1.8 mg/dL.
At basal conditions there were no significant differences between groups. At the end of follow-up, changes in the mean of systolic (-2.1 vs. 3.9% mmHg, p <0.05) and diastolic (-3.8 vs. 7.5% mmHg, p <0.05) blood pressures, HOMA-IR index (-46.5 vs. -5.4%, p <0.0001), fasting glucose (-12.3 vs. -1.8% mg/dL, p <0.05) and triglyceride levels (-47.4% vs. 10.1% mg/dL, p <0.0001) were significantly lower in the subjects who received MgCl2 compared with individuals in the control group.
Oral magnesium supplementation improves the metabolic profile and blood pressure of MONW individuals.

Copyright © 2014 IMSS. Published by Elsevier Inc. All rights reserved.

PMID: 24830937